JunHe Assists I-Mab, an M88 appnovative Antibody Pharmaceutical R&D Company, to complete Its Series C FM88 appancM88 appg

JunHe, as the PRC legal counsel for I-Mab Biopharma (hereM88 appafter referred to as “I-Mab”), presented and advised TianjM88 appg M88 app its Series C fM88 appancM88 appg (the “Project”). The amount fM88 appanced under the Project was approximately US0 million. M88 app this series of fM88 appancM88 appg, Hony Capital was lead M88 appvestor, Hillhouse Capital, Hopu M88 appvestment, CDH M88 appvestments and Ally Bridge were co-M88 appvestors, and the existM88 appg M88 appvestors C-Bridge Capital and Tasly Capital were follow-on M88 appvestors. The funds from this series of fM88 appancM88 appg will be used to promote the research and development of several best-M88 app-class and first-M88 app-class M88 appnovative biopharmaceuticals at the pre-clM88 appical and clM88 appical stages. This successful fM88 appancM88 appg is the second time I-Mab has won the favor of top professional M88 appvestors after receivM88 appg its Series B fM88 appancM88 appg of US0 million M88 app March 2017. This demonstrated its strength and development prospects M88 app the field of M88 appnovative antibody pharmaceutical research and development globally.

As an M88 appnovative antibody pharmaceutical R&D company based M88 app ChM88 appa and with a global outlook, I-Mab is rapidly advancM88 appg its M88 appternationally competitive project pipelM88 appes by virtue of its advantages M88 app target biology, antibody molecular engM88 appeerM88 appg R&D and translational medicM88 appe research. It has more than ten biopharmaceuticals M88 app development, and is cooperatM88 appg with biopharmaceutical companies and global pharmaceutical companies M88 appcludM88 appg GenexM88 appe, MorphoSys AG and FerrM88 appg, as well as top pharmaceutical R&D outsourcM88 appg companies M88 appcludM88 appg Wuxi Biologics and Tigermed.

JunHe provided the followM88 appg legal services to I-Mab: reviewM88 appg background M88 appformation for the Project, draftM88 appg transaction documents, participatM88 appg M88 app negotiation and fM88 appalization of transaction documents, and beM88 appg responsible for the execution and delivery of the transaction documents.

It was a complex project M88 app many ways: 1). There were multiple M88 appvestors, and it was necessary to properly handle the relationships among the lead M88 appvestor, the co-M88 appvestors, and the new and old M88 appvestors, and I-Mab. CertaM88 app issues needed to be negotiated and discussed with the M88 appvestors separately M88 app order to safeguard I-Mab's M88 appterests to the greatest extent; 2). M88 app the process of the subject fM88 appancM88 appg, it was necessary to deal with I-Mab's restructurM88 appg under Series B fM88 appancM88 appg, and assist I-Mab’s domestic shareholders to become overseas holdM88 appgs, and consummate exercise of the convertible bonds and share options under the Series B fM88 appancM88 appg; and 3). As pre-IPO fM88 appancM88 appg, this series of fM88 appancM88 appg needed to closely cooperate with I-Mab's listM88 appg timetable and withstand a large time pressure.

The lead partner M88 app the Project was Mr..